Synergy Offering to Bring in $90M for GI Drug Development
By Catherine Shaffer
Wednesday, April 10, 2013
Synergy Pharmaceuticals Inc., of New York, will boost its development of plecanatide, a candidate for gastrointestinal disorders, with an offering of $90 million of common stock. Plecanatide has the potential to treat disorders like chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.